CONSUMER NEWS    RECALLS    COMPLAINT FORM    SCAM ALERTS  


Complain about a product or service

Small Claims Guide | Class Actions | Lemon Law | FAQ | Resources | Newsletters | Spanish
Automotive    Education    Electronics    Family    Finance    Health    Homeowners    Shopping    Travel   
NEWS   Latest |  Archives |  Auto |  Cells, etc. |  Computers |  Financial |  Health |  Homeowners |  Parents |  Privacy |  Scams |  Seniors |  Travel

Merck Caves, Agrees To $4.85 Billion Vioxx Settlement

Pain reliever raised risk of heart attack, stroke





November 9, 2007    Spanish

Related Stories

First Vioxx Judgment Overturned On Appeal
Merck Agrees to Pay $58 Million to Settle Vioxx Claims
Researchers Claim Merck Cooked Vioxx Data
Common Pain Relievers May Boost Muscle Mass
More Painkillers Can Cause More Pain
Merck Caves, Agrees To $4.85 Billion Vioxx Settlement
New York Sues Vioxx Maker over Drug’s Risks
Merck Wins Vioxx Case In Illinois
Judge Rules Out Vioxx "Super" Class Action
FDA Critic Blasts Merck's Vioxx Replacement
Merck Loses New Orleans Vioxx Case
Merck Wins Latest Vioxx Suit
Vioxx Study Authors Backtrack On Claim
Older Painkillers May Increase Heart Attack Risk
More about Vioxx
---
Other NSAIDs
Bextra
Celebrex
Dangers of Other Vioxx-Type Drugs
Vioxx Alternatives
Aleve Ingredient Seen as Health Risk

After insisting it would contest each of the thousands of product liability law suits over Vioxx, pharmaceutical giant Merck, Inc. has agreed to settle claims over the withdrawn painkiller for $4.85 billion.

Merck withdrew Vioxx from the market in September 2004 after tests indicated the highly popular arthritis drug increased the risk of heart attack and stroke in patients taking it. More than 27,000 consumers or their family members filed suit against Merck as a result.

In the last three years, only a handful of the cases have gone to trial.

Merck has won some of the more recent trials, but pressure mounted on company executives to do something to stem the escalating legal costs of defending those cases. Judges in California, New Jersey, and Louisiana, who have heard most of the cases, also pressed both sides to reach a settlement.

Under the terms of the agreement, 85 percent of the plaintiffs must sign off on it for it to become binding. Plaintiffs would receive payments depending on the severity of their injuries and the length of time they took the drug.

If finalized, it would become the largest settlement in the U.S. this year and could rank among the largest in U.S. history. Prior to its withdrawal from the market, millions of consumers were taking Vioxx for arthritis and other pain. Merck’s Vioxx sales totaled $2.5 billion in 2003.

A New NSAID

FDA approved Vioxx in 1999 for the reduction of pain and inflammation caused by osteoarthritis, as well as for acute pain and for the treatment of menstrual pain. It was the second of a new kind of NSAID (Cox-2 selective) approved by FDA.

Subsequently, FDA approved Vioxx to treat the signs and symptoms of rheumatoid arthritis in adults and children.

At the time that Vioxx and other Cox-2 selective NSAIDs were approved, it was hoped that they would have a lower risk of gastrointestinal ulcers and bleeding than other NSAIDs, such as ibuprofen and naproxen. Vioxx was the only NSAID demonstrated to have a lower rate of these side effects.

Merck contacted FDA on September 27, 2004, to request a meeting and to advise the agency that the long-term study of Vioxx in patients at increased risk of colon polyps had been halted.

Merck and FDA officials met the next day, September 28, and during that meeting the company informed FDA of its decision to remove Vioxx from the market voluntarily.



Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.


Consumer News

July 20 2008

Recent Recalls & Safety Alerts

Print, mail, etc.






FREE CONSUMER NEWSLETTERS

The Daily Consumer
Afternoons M-F

Sign up now!


Consumer News & Alerts
Every Sunday

Sign up now!


Knowledge is free.
Knowledge is power.



Back to the top |

Advertisement


Home | Rogues Gallery | Good Guys | Complaint Form | News | Recalls | Search | Video | FAQ |
Consumer Resources | Small Claims Guide | Lemon Law | Newsletter | Contact Us
Advertise With Us | Testimonials | Newsroom | RSS Feeds | Radio | Job Postings




Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2008 ConsumerAffairs.com Inc.  All Rights Reserved.